GILD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$68.83 |
52 Week High | US$87.87 |
52 Week Low | US$62.07 |
Beta | 0.22 |
11 Month Change | 7.65% |
3 Month Change | -6.03% |
1 Year Change | -9.45% |
33 Year Change | -0.43% |
5 Year Change | -0.25% |
Change since IPO | 10,776.85% |
Recent News & Updates
Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Recent updates
Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Jan 15What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You
Dec 25Shareholder Returns
GILD | US Biotechs | US Market | |
---|---|---|---|
7D | 0.5% | -0.3% | 0.3% |
1Y | -9.4% | 11.0% | 22.5% |
Return vs Industry: GILD underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: GILD underperformed the US Market which returned 22.5% over the past year.
Price Volatility
GILD volatility | |
---|---|
GILD Average Weekly Movement | 3.6% |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GILD has not had significant price volatility in the past 3 months.
Volatility Over Time: GILD's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GILD fundamental statistics | |
---|---|
Market cap | US$86.35b |
Earnings (TTM) | US$485.00m |
Revenue (TTM) | US$27.45b |
176.8x
P/E Ratio3.1x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GILD income statement (TTM) | |
---|---|
Revenue | US$27.45b |
Cost of Revenue | US$6.17b |
Gross Profit | US$21.28b |
Other Expenses | US$20.80b |
Earnings | US$485.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | 0.39 |
Gross Margin | 77.52% |
Net Profit Margin | 1.77% |
Debt/Equity Ratio | 144.3% |
How did GILD perform over the long term?
See historical performance and comparison